# **Summary of Product Characteristics**

# **1 NAME OF THE MEDICINAL PRODUCT**

Xyzal 5 mg film-coated tablets

# **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 5 mg levocetirizine dihydrochloride.

Excipient(s) with known effect Lactose monohydrate

For the full list of excipients, see section 6.1.

#### **3 PHARMACEUTICAL FORM**

Film-coated tablet

*Product imported from the UK & Czech Republic* White to off-white, oval, film-coated tablet with a Y logo on one side.

## **4 CLINICAL PARTICULARS**

As per PA0891/003/001

### **5 PHARMACOLOGICAL PROPERTIES**

As per PA0891/003/001

#### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

Microcrystalline cellulose Lactose monohydrate Colloidal anhydrous silica Magnesium stearate Hypromellose (E464) Titanium dioxide (E 171) Macrogol 400

#### **6.2 Incompatibilities**

Not applicable.

#### 6.3 Shelf life

The shelf life expiry date of this product shall be the date shown on the container and outer package of the product on the market in the country of origin.

#### 6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

## 6.5 Nature and contents of container

Cardboard outer containing blister strips. Pack size: 28 or 30. Not all pack sizes may be marketed.

## 6.6 Special precautions for disposal

No special requirements.

# **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

Imbat Limited Unit L2 North Ring Business Park Santry Dublin 9

# **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA1151/052/001

## 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of First Authorisation: 19th December 2007

## **10 DATE OF REVISION OF THE TEXT**

April 2018